Publicacions (15) Publicacions de María Pilar Andueza Arrieta

2024

  1. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

2021

  1. Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients

    Cytokine, Vol. 141

  2. Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils

    European Journal of Immunology, Vol. 51, Núm. 9, pp. 2274-2280

  3. Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

    Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

  2. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients

    Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348

2019

  1. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

  2. The dynamic use of EGFR mutation analysis in cell-free DNA as a follow-up biomarker during different treatment lines in non-small-cell lung cancer patients

    Disease Markers, Vol. 2019

2018

  1. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

2017

  1. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

    Tumor Biology, Vol. 37, Núm. 10, pp. 13687-13694

  2. Tumor-Produced Interleukin-8 Attracts human myeloid-derived suppressor cells and elicits extrusion of Neutrophil Extracellular Traps (NETs)

    Clinical Cancer Research, Vol. 22, Núm. 15, pp. 3924-3936

2014

  1. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

    Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707